43 of 44 Patients Achieved Sustained Virologic Response (SVR)
Share
Follow Us
Merck hepatitis C drugs shine in easier to treat patients: study
By Bill Berkrot
Apr 10, 2014
(Reuters) – A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.
Results of the study called C-Worthy were presented on Thursday at the annual meeting of the European Association for the Study of the Liver (EASL) in London. Researchers are due on Friday to present results of how the Merck pills fared in more difficult to treat patients, such as those who failed to be helped by prior treatments and those with more advanced liver disease.
Continue reading this entire article:
http://www.reuters.com/article/2014/04/10/us-hepatitis-merck-idUSBREA390B120140410
